- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT02505334
A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.
A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus
Tutkimuksen yleiskatsaus
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 3
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Annaka-shi, Gunma, Japani, 379 0116
- Novo Nordisk Investigational Site
-
Chitose, Hokkaido, Japani, 066-0032
- Novo Nordisk Investigational Site
-
Chuo-ku Tokyo, Japani, 103-0027
- Novo Nordisk Investigational Site
-
Chuo-ku,, Japani, 104 0061
- Novo Nordisk Investigational Site
-
Chuo-ku, Tokyo, Japani, 103 0027
- Novo Nordisk Investigational Site
-
Chuo-ku, Tokyo, Japani, 103 0002
- Novo Nordisk Investigational Site
-
Fukuoka-shi, Fukuoka, Japani
- Novo Nordisk Investigational Site
-
Higashiosaka-shi, Osaka, Japani
- Novo Nordisk Investigational Site
-
Hokkaido, Japani, 078-8236
- Novo Nordisk Investigational Site
-
Ichikawa-shi, Chiba, Japani
- Novo Nordisk Investigational Site
-
Iruma-shi, Saitama, Japani, 358 0011
- Novo Nordisk Investigational Site
-
Izumisano-shi, Japani, 598 0048
- Novo Nordisk Investigational Site
-
Kashiwara-shi, Osaka, Japani, 582 0005
- Novo Nordisk Investigational Site
-
Kawagoe-shi, Saitama, Japani, 350 0851
- Novo Nordisk Investigational Site
-
Kobe-shi, Hyogo, Japani
- Novo Nordisk Investigational Site
-
Kumamoto-shi,Kumamoto, Japani, 862 0976
- Novo Nordisk Investigational Site
-
Mito-shi, Ibaraki, Japani, 310-0845
- Novo Nordisk Investigational Site
-
Mito-shi, Ibaraki, Japani
- Novo Nordisk Investigational Site
-
Miyazaki-shi, Japani, 880 0034
- Novo Nordisk Investigational Site
-
Naka-shi, Ibaraki, Japani, 311 0113
- Novo Nordisk Investigational Site
-
Neyagawa-shi, Osaka, Japani
- Novo Nordisk Investigational Site
-
Nishinomiya-shi, Hygo, Japani, 662 0971
- Novo Nordisk Investigational Site
-
Nishinomiya-shi, Hyogo, Japani, 663-8501
- Novo Nordisk Investigational Site
-
Oita-shi, Japani, 870 0039
- Novo Nordisk Investigational Site
-
Okawa-shi, Fukuoka, Japani, 831 0016
- Novo Nordisk Investigational Site
-
Osaka-shi, Osaka, Japani, 553 0003
- Novo Nordisk Investigational Site
-
Osaka-shi, Osaka, Japani, 5590012
- Novo Nordisk Investigational Site
-
Oyama-shi, Tochigi, Japani, 323 0022
- Novo Nordisk Investigational Site
-
Saga-shi,Saga, Japani, 849 0937
- Novo Nordisk Investigational Site
-
Sapporo-shi, Hokkaido, Japani, 060 0062
- Novo Nordisk Investigational Site
-
Sapporo-shi, Hokkaido, Japani, 060-0001
- Novo Nordisk Investigational Site
-
Sapporo-shi, Hokkaido, Japani, 062 0007
- Novo Nordisk Investigational Site
-
Sappro-shi, Hokkaido, Japani, 060 8648
- Novo Nordisk Investigational Site
-
Shimotsuke-shi, Tochigi, Japani, 329 0433
- Novo Nordisk Investigational Site
-
Shinjuku-ku, Tokyo, Japani, 160-0008
- Novo Nordisk Investigational Site
-
Shizuoka-shi, Japani, 424 0853
- Novo Nordisk Investigational Site
-
Suita-shi, Osaka, Japani, 565-0853
- Novo Nordisk Investigational Site
-
Takatsuki-shi, Osaka, Japani, 569 1096
- Novo Nordisk Investigational Site
-
Tokyo, Japani, 181-0013
- Novo Nordisk Investigational Site
-
Tokyo, Japani, 103-0028
- Novo Nordisk Investigational Site
-
Tokyo, Japani, 169-0073
- Novo Nordisk Investigational Site
-
Tokyo, Japani, 105-8471
- Novo Nordisk Investigational Site
-
Tokyo, Japani, 123-0845
- Novo Nordisk Investigational Site
-
Tokyo, Japani, 144-0051
- Novo Nordisk Investigational Site
-
Yokohama, Kanagawa, Japani, 236-0004
- Novo Nordisk Investigational Site
-
Yokohama-shi, Japani, 235 0045
- Novo Nordisk Investigational Site
-
Yokohama-shi Kanagawa, Japani, 232-0064
- Novo Nordisk Investigational Site
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Male or female Japanese subjects at least 20 years of age at the time of informed consent
- Type 2 diabetes subjects (diagnosed clinically) for at least 6 months prior to screening
- HbA1c 7.5-10.0% [58 mmol/mol-86 mmol/mol] (both inclusive)
- Subjects on stable therapy with one OAD (oral antidiabetic drug) (stable therapy is defined as unchanged medication and unchanged dose) for for at least 60 days before screening according to approved Japanese labelling
Exclusion Criteria:
- Treatment with insulin within 12 weeks prior to screening
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 60 days before screening
- Screening calcitonin equal or above 50 ng/l
- History of pancreatitis (acute or chronic)
- Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2)
- Subjects presently classified as being in New York Heart Association (NYHA) Class IV
- Within the past 180 days any of the following: myocardial infarction, stroke or hospitalisation for unstable angina and/or transient ischemic attack
- Diagnosis of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer, polyps and in-situ carcinomas)
- Any condition which, in the opinion of the investigator might jeopardise subject's safety or compliance with the protocol
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Liraglutide 1.8 mg
The total trial duration for the 1.8 mg/day treatment arm will be approximately 67 weeks, consisting of 2 weeks screening period, a 12 weeks run-in period, a 26-week main treatment period, a safety extension period of 26 weeks and a follow-up visit.
|
Injected subcutaneously s.c.
(under the skin) once daily.
|
Active Comparator: Liraglutide 0.9 mg
The total trial duration for the 0.9 mg/day treatment arm will be approximately 41 weeks, consisting of 2 weeks screening period, a 12 weeks run-in period, a 26-week treatment period, and a follow-up visit.
|
Injected subcutaneously s.c.
(under the skin) once daily.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Change in Glycosylated Haemoglobin (HbA1c) (Week 26)
Aikaikkuna: Week 0, Week 26
|
Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated after 26 weeks of treatment.
The change from baseline in the response after 26 weeks of treatment is analysed using an analysis of covariance (ANCOVA) model with treatment as a fixed effect and baseline response as a covariate.
|
Week 0, Week 26
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Change in HbA1c (Week 52)
Aikaikkuna: Week 0, Week 52
|
Change from baseline (week 0) in HbA1c was evaluated after 52 weeks of treatment.
|
Week 0, Week 52
|
Responder for HbA1c Below 7.0% (53 mmol/Mol)
Aikaikkuna: Week 26 and Week 52
|
Reported results are number of subjects who achieved HbA1c target below 7.0% after 26 weeks and 52 weeks of treatment, respectively.
|
Week 26 and Week 52
|
Responder for HbA1c Below or Equal to 6.5% (48 mmol/Mol)
Aikaikkuna: Week 26 and Week 52
|
Reported results are number of subjects who achieved HbA1c target below or equal to 6.5% after 26 weeks and 52 weeks of treatment, respectively.
|
Week 26 and Week 52
|
Responder for HbA1c Below 7.0% Without Weight Gain
Aikaikkuna: Week 26 and Week 52
|
Reported results are number of subjects who achieved HbA1c target below 7.0% without weight gain after 26 weeks and 52 weeks of treatment, respectively.
|
Week 26 and Week 52
|
Responder for HbA1c Below 7.0% Without Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes
Aikaikkuna: Week 26 and Week 52
|
Reported results are subjects with HbA1c <7.0% after 26 weeks and 52 weeks of treatment, respectively without treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes.
Severe or BG confirmed symptomatic hypoglycaemia: severe as per ADA classification or BG confirmed by plasma glucose (PG) value <3.1 mmol/L with symptoms consistent with hypoglycaemia.
Severe hypoglycaemia as per ADA: episode requiring assistance of another person to actively administer carbohydrate/glucagon, or take other corrective actions.
PG levels may not be available during an event, but neurological recovery following the return of PG to normal is considered sufficient evidence that the event was induced by a low PG level.
Treatment emergent: episode with onset date on or after randomisation (from week (wk)0) and no later than 7 days after the last day on liraglutide (maximum till wk26+7days and wk52+7days).
Hence, the following shown 'Time Frame' should be read as 'Wk26+7days and Wk52+7days'
|
Week 26 and Week 52
|
Change in Self-Measured Blood Glucose (SMBG) 7-point Profile: 7-point Profile (Individual Points in the Profile)
Aikaikkuna: Week 0 and Week 26 and Week 52
|
Reported results are 7-point SMBG values at week 0, week 26 and week 52. The 7-point profile blood glucose levels were measured at the following time points always starting with the first:
|
Week 0 and Week 26 and Week 52
|
Change in SMBG 7-point Profile: Mean of 7-point Profile
Aikaikkuna: Week 0, Week 26, Week 52
|
Change from baseline (week 0) in mean of the SMBG 7-point profile was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26, Week 52
|
Change in SMBG 7-point Profile: Mean of Postprandial Increments (From Before Meal to 90 Minutes After for Breakfast, Lunch and Dinner)
Aikaikkuna: Week 0, Week 26, Week 52
|
Change from baseline (week 0) in mean of postprandial increments (from before meal to 90 minutes after for breakfast, lunch and dinner) of the SMBG 7-point profile was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26, Week 52
|
Change in Fasting Plasma Glucose (FPG)
Aikaikkuna: Week 0, Week 26, Week 52
|
Change from baseline (week 0) in FPG was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26, Week 52
|
Change in Waist Circumference
Aikaikkuna: Week 0, Week 26, Week 52
|
Change from baseline (week 0) in waist circumference was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26, Week 52
|
Change in Body Weight
Aikaikkuna: Week 0, Week 26, Week 52
|
Change from baseline (week 0) in body weight was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26, Week 52
|
Change in Body Mass Index (BMI)
Aikaikkuna: Week 0, Week 26, Week 52
|
Change from baseline (week 0) in BMI was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26, Week 52
|
Change in Blood Pressure (Systolic and Diastolic)
Aikaikkuna: Week 0, Week 26, Week 52
|
Change from baseline (week 0) in systolic blood pressure (SBP) and diastolic blood pressure (DBP) was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26, Week 52
|
Fasting C-peptide
Aikaikkuna: Week 26 and Week 52
|
Fasting C-peptide was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 26 and Week 52
|
Fasting Insulin
Aikaikkuna: Week 26 and Week 52
|
Fasting insulin was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 26 and Week 52
|
Fasting Glucagon
Aikaikkuna: Week 26 and Week 52
|
Fasting glucagon was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 26 and Week 52
|
Proinsulin
Aikaikkuna: Week 26 and Week 52
|
Proinsulin was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 26 and Week 52
|
Proinsulin/Insulin
Aikaikkuna: Week 26 and Week 52
|
Proinsulin/insulin was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 26 and Week 52
|
Homeostasis Model Assessment of Beta-cell Function (HOMA-B)
Aikaikkuna: Week 26 and Week 52
|
HOMA-B was evaluated after 26 weeks and 52 weeks of treatment, respectively.
HOMA-B is an index of beta-cell function and was calculated as: HOMA-B=[(20 x fasting insulin in µU/mL)/(FPG in mmol/L-3.5)].
|
Week 26 and Week 52
|
Homeostasis Model Assessment as an Index of Insulin Resistance (HOMA-IR)
Aikaikkuna: Week 26 and Week 52
|
HOMA-IR was evaluated after 26 weeks and 52 weeks of treatment, respectively.
HOMA-IR is an index of insulin resistance and was calculated as: HOMA-IR= fasting insulin (μU/mL) x FPG (mmol/L)/22.5.
|
Week 26 and Week 52
|
Total Cholesterol
Aikaikkuna: Week 26 and Week 52
|
Total cholesterol was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 26 and Week 52
|
Low Density Lipoprotein (LDL) Cholesterol
Aikaikkuna: Week 26 and Week 52
|
LDL was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 26 and Week 52
|
High Density Lipoprotein (HDL) Cholesterol
Aikaikkuna: Week 26 and Week 52
|
HDL was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 26 and Week 52
|
Very Low Density Lipoprotein (VLDL) Cholesterol
Aikaikkuna: Week 26 and Week 52
|
VLDL was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 26 and Week 52
|
Triglycerides
Aikaikkuna: Week 26 and Week 52
|
Triglycerides were evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 26 and Week 52
|
Free Fatty Acids
Aikaikkuna: Week 26 and Week 52
|
Free fatty acids were evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 26 and Week 52
|
Number of Treatment Emergent Adverse Events
Aikaikkuna: Weeks 0-26 and Weeks 0-52
|
Treatment emergent adverse events (TEAEs) were evaluated during the 26-week and 52-week treatment period, respectively.
TEAE for weeks 0-26: Event that has onset date on or after randomisation (from week 0) and no later than seven days after the last day on liraglutide (maximum till week 26 + 7 days).
TEAE for weeks 0-52: Event that has onset date on or after randomisation (from week 0) and no later than seven days after the last day on liraglutide (maximum till week 52 + 7 days).
Hence, the following shown 'Time Frame' should be read as 'Weeks 0-26 + 7 days and Weeks 0-52 + 7 days'.
|
Weeks 0-26 and Weeks 0-52
|
Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
Aikaikkuna: Weeks 0-26 and Weeks 0-52
|
Treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes were evaluated during the 26-week and 52-week treatment period, respectively.
Severe or BG confirmed symptomatic hypoglycaemia (hypo):An episode that was severe according to the ADA classification or BG confirmed by a PG value <3.1 mmol/L with symptoms consistent with hypo.
ADA definition of severe hypo:episode requiring assistance of another person to actively administer carbohydrate/glucagon, or take other corrective actions.
PG levels may not be available during an event, but neurological recovery following the return of PG to normal is considered sufficient evidence that the event was induced by a low PG level.
Treatment emergent: episode with onset date on or after randomisation (from week (wk) 0) and no later than 7 days after the last day on liraglutide (maximum till wk 26 and wk 52, respectively + 7 days).
Hence, the following shown 'Time Frame' should be read as 'wk 0-26+7 days and wk 0-52+7 days'.
|
Weeks 0-26 and Weeks 0-52
|
Number of Treatment Emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
Aikaikkuna: Weeks 0-26 and Weeks 0-52
|
Treatment emergent nocturnal severe or BG confirmed symptomatic hypoglycaemic episodes were evaluated during the26-week and 52-week treatment period, respectively.
Nocturnal hypoglycaemic episodes: Those occurring between 00:01 and 05:59 hours, both inclusive.
Severe or BG confirmed symptomatic hypoglycaemia: episode that was severe according to the ADA classification or BG confirmed by a PG value <3.1 mmol/L with symptoms consistent with hypoglycaemia.
Treatment emergent: episode with onset date on or after randomisation (from week 0) and no later than 7 days after the last day on liraglutide (maximum till week 26 and week 52, respectively + 7 days).
Hence, the following shown 'Time Frame' should be read as 'Week 0-26 + 7 days and Week 0-52 + 7 days'.
|
Weeks 0-26 and Weeks 0-52
|
Number of Treatment Emergent Hypoglycaemic Episodes According to ADA Definition
Aikaikkuna: Weeks 0-26 and Weeks 0-52
|
American Diabetes Association (ADA) classification of hypoglycaemia:
|
Weeks 0-26 and Weeks 0-52
|
Change in Pulse
Aikaikkuna: Week 0, Week 26, Week 52
|
Change from baseline (week 0) in pulse was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26, Week 52
|
Change in Physical Examination
Aikaikkuna: Week 0 and Week 26 and Week 52
|
Reported results are physical examination outcomes at week (wk) 0, wk 26 and wk 52. Physical examination consisted of the following listed examinations and the outcome of each examination was evaluated as: 1) normal, 2) abnormal, not clinically significant (NCS) or 3) abnormal, clinically significant (CS).
|
Week 0 and Week 26 and Week 52
|
Change in Eye Examination
Aikaikkuna: Week 0 and Week 26 and Week 52
|
Reported results are eye examination (ophthalmoscopy) outcomes at week 0, week 26 and week 52.
Ophthalmoscopy outcomes for both left and right eye were evaluated as: 1) normal, 2) abnormal, NCS or 3) abnormal, CS.
|
Week 0 and Week 26 and Week 52
|
Change in Electrocardiogram (ECG)
Aikaikkuna: Week 0 and Week 26 and Week 52
|
Reported results are ECG outcomes at week 0, week 26 and week 52.
ECG outcomes were evaluated as: 1) normal, 2) abnormal, NCS or 3) abnormal, CS.
|
Week 0 and Week 26 and Week 52
|
Change in Biochemistry: Creatinine
Aikaikkuna: Week 0, Week 26, Week 52
|
Change from baseline (week 0) in creatinine was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26, Week 52
|
Change in Biochemistry: eGFR
Aikaikkuna: Week 0, Week 26, Week 52
|
Change from baseline (week 0) in estimated glomerular filtration rate (eGFR) was evaluated after 26 weeks and 52 weeks of treatment, respectively.
eGFR was evaluated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, mL/min/1.73m^2.
|
Week 0, Week 26, Week 52
|
Change in Biochemistry: Alanine Aminotransferase
Aikaikkuna: Week 0, Week 26, Week 52
|
Change from baseline (week 0) in alanine aminotransferase was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26, Week 52
|
Change in Biochemistry: Aspartate Aminotransferase
Aikaikkuna: Week 0, Week 26, Week 52
|
Change from baseline (week 0) in aspartate aminotransferase was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26, Week 52
|
Change in Biochemistry: Alkaline Phosphatase
Aikaikkuna: Week 0, Week 26, Week 52
|
Change from baseline (week 0) in alkaline phosphatase was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26, Week 52
|
Change in Biochemistry: Sodium
Aikaikkuna: Week 0, Week 26, Week 52
|
Change from baseline (week 0) in sodium was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26, Week 52
|
Change in Biochemistry: Potassium
Aikaikkuna: Week 0, Week 26, Week 52
|
Change from baseline (week 0) in potassium was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26, Week 52
|
Change in Biochemistry: Albumin
Aikaikkuna: Week 0, Week 26, Week 52
|
Change from baseline (week 0) in albumin was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26, Week 52
|
Change in Biochemistry: Total Bilirubin
Aikaikkuna: Week 0, Week 26, Week 52
|
Change from baseline (week 0) in total bilirubin was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26, Week 52
|
Change in Biochemistry: Urea
Aikaikkuna: Week 0, Week 26, Week 52
|
Change from baseline (week 0) in urea was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26, Week 52
|
Change in Biochemistry: Creatine Kinase
Aikaikkuna: Week 0, Week 26, Week 52
|
Change from baseline (week 0) in creatine kinase was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26, Week 52
|
Change in Biochemistry: Calcium
Aikaikkuna: Week 0, Week 26, Week 52
|
Change from baseline (week 0) in calcium was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26, Week 52
|
Change in Biochemistry: Albumin Corrected Calcium
Aikaikkuna: Week 0, Week 26, Week 52
|
Change from baseline (week 0) in albumin corrected calcium was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26, Week 52
|
Change in Biochemistry: Amylase
Aikaikkuna: Week 0, Week 26, Week 52
|
Change from baseline (week 0) in amylase was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26, Week 52
|
Change in Biochemistry: Lipase
Aikaikkuna: Week 0, Week 26, Week 52
|
Change from baseline (week 0) in lipase was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26, Week 52
|
Change in Haematology: Haemoglobin
Aikaikkuna: Week 0, Week 26, Week 52
|
Change from baseline (week 0) in haemoglobin was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26, Week 52
|
Change in Haematology: Haematocrit
Aikaikkuna: Week 0, Week 26, Week 52
|
Change from baseline (week 0) in haematocrit was evaluated after 26 weeks and 52 weeks of treatment, respectively.
Haematocrit is the ratio of the volume of red blood cells to the total volume of blood.
|
Week 0, Week 26, Week 52
|
Change in Haematology: Thrombocytes
Aikaikkuna: Week 0, Week 26 and Week 52
|
Change from baseline (week 0) in thrombocytes (platelets) was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26 and Week 52
|
Change in Haematology: Erythrocytes
Aikaikkuna: Week 0, Week 26 and Week 52
|
Change from baseline (week 0) in erythrocytes was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26 and Week 52
|
Change in Haematology: Leukocytes
Aikaikkuna: Week 0, Week 26 and Week 52
|
Change from baseline (week 0) in leukocytes was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26 and Week 52
|
Change in Haematology: Eosinophils
Aikaikkuna: Week 0, Week 26 and Week 52
|
Change from baseline (week 0) in eosinophils was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26 and Week 52
|
Change in Haematology: Neutrophils
Aikaikkuna: Week 0, Week 26 and Week 52
|
Change from baseline (week 0) in neutrophils was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26 and Week 52
|
Change in Haematology: Basophils
Aikaikkuna: Week 0, Week 26 and Week 52
|
Change from baseline (week 0) in basophils was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26 and Week 52
|
Change in Haematology: Monocytes
Aikaikkuna: Week 0, Week 26 and Week 52
|
Change from baseline (week 0) in monocytes was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26 and Week 52
|
Change in Haematology: Lymphocytes
Aikaikkuna: Week 0, Week 26 and Week 52
|
Change from baseline (week 0) in lymphocytes was evaluated after 26 weeks and 52 weeks of treatment, respectively.
|
Week 0, Week 26 and Week 52
|
Change in Calcitonin
Aikaikkuna: Week 0 and Week 26 and Week 52
|
Reported results are number of subjects with low, normal or high calcitonin values at week 0, week 26 and week 52.
Number of subjects analyzed = number of subjects contributed to the analysis for individual time point.
Calcitonin values were categorised as low, normal or high.
|
Week 0 and Week 26 and Week 52
|
Yhteistyökumppanit ja tutkijat
Sponsori
Julkaisuja ja hyödyllisiä linkkejä
Hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- NN2211-4174
- U1111-1164-5462 (Muu tunniste: WHO)
- JapicCTI-152975 (Rekisterin tunniste: JAPIC)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Diabetes mellitus, tyyppi 2
-
Griffin HospitalCalifornia Walnut CommissionValmisTYYPIN DIABETES MELLITUS 2Yhdysvallat
-
Diabetes Free, Inc.Ei vielä rekrytointiaDiabetes mellitus tyyppi 2 - Insuliinilla hoidettu
-
DiabeloopUniversity Hospital, Grenoble; AGIR à Dom; Icadom; Centre Hospitalier Annecy... ja muut yhteistyökumppanitValmisDiabetes mellitus tyyppi 2 - Insuliinilla hoidettuRanska
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Ei vielä rekrytointiaTyypin 2 diabetes mellitus
-
Endogenex, Inc.Ei vielä rekrytointiaDiabetes mellitus, tyyppi 2 | Diabetes | Tyypin 2 diabetes mellitus | Tyypin 2 diabetes | Tyypin 2 diabetes
-
Nanjing First Hospital, Nanjing Medical UniversityRekrytointiTyypin 2 diabetes mellitusKiina
-
Xiangya Hospital of Central South UniversityRekrytointi
-
University of Alabama at BirminghamValmisTyypin 2 diabetes mellitusYhdysvallat
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...ValmisTyypin 2 diabetes mellitusYhdistynyt kuningaskunta
-
Universiti Sains MalaysiaValmis
Kliiniset tutkimukset liraglutide
-
The First Affiliated Hospital of Xiamen UniversityTuntematonYlipaino ja lihavuus | Hyperglykemia (diabeettinen) | Tyypin 2 diabetespotilaatKiina
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...TuntematonLihavuus | Tyypin 2 diabetes mellitus | Kognitiivinen rajoiteKiina